This discrepancy in contrary results may be due to the fact that we have used a different, more clinically available BRAF inhibitor drug, PLX4032 (vemurafenib) and at suboptimal dosage, but nevertheless should receive more attention since the BRAF inhibitor is not always sensitive in BRAF (V600E) mutant thyroid cancer in reality. This evidence concerns the gene BRAF and thyroid gland carcinoma.